10-K: SIGA Technologies Reports Strong 2024 Results, Navigates Evolving Biodefense Landscape

SIGA Technologies reports its financial results for the year ended December 31, 2024, highlighting continued sales of TPOXX and strategic advancements in government contracts and international expansion.

Summary

• SIGA Technologies, Inc. reported its financial results for the year ended December 31, 2024.
• The company sells TPOXX, an antiviral drug for the treatment of human smallpox disease, to the U.S. Government and international governments.
• Total revenues for 2024 were $138.7 million, including $133.3 million from product sales and supportive services and $5.4 million from research and development activities.
• International sales reached $23.0 million in 2024, with deliveries of oral TPOXX to 13 countries.
• The company had sales of approximately $10 million with the U.S. Department of Defense (DoD) in 2024.
• SIGA is pursuing a potential FDA label expansion of oral TPOXX for smallpox post-exposure prophylaxis (PEP), targeting a Supplemental NDA submission in the next twelve months.
• The 19C BARDA Contract contemplates up to approximately $602.5 million of payments, of which approximately $51.7 million of payments are included within the base period of performance, approximately $519.6 million of payments are related to exercised options and up to approximately $31.2 million of payments are currently specified as unexercised options.
• Net income for the year was $59.2 million, with basic earnings per share of $0.83 and diluted earnings per share of $0.82.
• As of December 31, 2024, SIGA had $155.4 million in cash and cash equivalents.
• The Board of Directors declared a special dividend of $0.60 per share, paid on April 11, 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong financial results and ongoing government contracts. However, there are risks associated with reliance on government funding and competition in the biodefense market.

Positives

• SIGA achieved $138.7 million in total revenues for 2024.
• International sales increased to $23.0 million, expanding the company's global reach.
• The company maintains a strong cash position with $155.4 million in cash and cash equivalents.
• SIGA is actively pursuing a label expansion for TPOXX, potentially increasing its market.
• The company has a significant contract with BARDA, providing a stable revenue stream.

Negatives

• The PALM 007 study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the DRC with mpox who received TPOXX compared to patients who received placebo.
• An interim analysis of data from the STOMP study showed that TPOXX did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placebo in patients with mild to moderate clade II mpox.
• The Company believes the ongoing trials are likely to yield similar results.
• The Company estimates that sales of the IV formulation under this contract (under current terms), assuming the remaining IV FDP Option was exercised, would have a gross margin (sales less cost of sales, as a percentage of sales) that is less than 40%.

Risks

• The majority of potential revenue under the 19C BARDA Contract is tied to options all but one of which have been exercised and the remaining option may or may not be exercised at the sole discretion of BARDA.
• The funding of government programs, which fund BARDAs purchases under the 19C BARDA Contract and are expected to fund any new contract to supply TPOXX to the U.S. Government, is subject to Congressional appropriations, generally made on a fiscal year basis even though a program may continue for several years.
• If the remaining option under the 19C BARDA Contract is not exercised, or we are unable to enter into a new contract to supply TPOXX to the U.S. Government on favorable terms, if at all, including because levels of government expenditures and authorizations for biodefense decrease or shift to other programs, changes in the U.S. administration, or for any other reason, our business, financial condition, results of operations and prospects may suffer materially.
• If third parties on whom we rely for manufacturing and raw materials of TPOXX, and managing our inventory, do not perform as contractually required or as we expect, we may not be able to successfully satisfy our obligations under any contracts, including the 19C BARDA Contract and any future U.S. Government procurement contract, and our business would suffer.
• Growth of our business may be impacted significantly by our success in completing development and commercialization of drug candidates, new formulations or additional indications for TPOXX.
• Our ability to compete may decrease if we do not adequately protect our intellectual property rights.

Future Outlook

The company is targeting a Supplemental NDA submission for a smallpox PEP indication in the next twelve months. The company believes the ongoing trials are likely to yield similar results.

Industry Context

The report highlights the continued awareness of biological outbreak risks and threats, with the U.S. Government remaining the largest source of funding for medical countermeasure research and development. The company faces competition from major pharmaceutical companies and other biotechnology firms in the medical countermeasure sector.

Comparison to Industry Standards

• The biotechnology and pharmaceutical industries are characterized by rapidly evolving technology and intense competition.
• Our current and potential competitors include many major pharmaceutical companies, many of which have significant financial, technical and marketing resources.
• Biotechnology and other pharmaceutical competitors in the medical countermeasure sector include, but are not limited to, Emergent BioSolutions Inc. and Bavarian Nordic A/S.

Related Party Transactions

• In May 2017, we entered into a new 10-year lease with a related party to let 3,200 square feet in New York, NY to serve as our corporate headquarters.

Stakeholder Impact

• Shareholders received a special dividend of $0.60 per share.
• The company's performance is dependent on government funding and contracts, impacting its ability to deliver value to shareholders.
• The company's activities contribute to public health security by providing medical countermeasures for biological threats.

Next Steps

• The company is targeting a Supplemental NDA submission for a smallpox PEP indication in the next twelve months.
• The company will continue to monitor the results of ongoing mpox clinical trials.

Key Dates